tiprankstipranks
Sophia Genetics, Qiagen team  on next-generation sequencing
The Fly

Sophia Genetics, Qiagen team on next-generation sequencing

Sophia Genetics (SOPH) announced a new partnership with Qiagen that will pair QIAseq reagent technology with the SOPHiA DDM platform to enhance tumor analysis through next-generation sequencing NGS . The partnership will allow customers to order QIAseq panels that can be processed through SOPHiA DDM , a cloud-based platform that analyzes data from various sources to enable entirely new research perspectives. The partnership will initially support somatic variant detection using QIAseq Targeted DNA Pro panels for homologous recombination repair HRR , a special type of biomarker test to find tumors that have certain mutations that may make them sensitive to PARP inhibitors in oncology…The partnership with SOPHiA GENETICS is planned to be expanded to other areas of analysis, including the use of QIAseq panels custom-made solutions. It is the inaugural partnership in QIAGEN’s QIAseq Platform Partnership. NGS has the potential to revolutionize the diagnosis and treatment of cancers and rare diseases but creates extremely large, complex, and noisy datasets for analysis. Without the right analytical technology, pinpointing causative variants and obtaining actionable insights from NGS data requires specialist skills, multiple resources, and considerable time. The SOPHiA DDM(TM) Platform uses machine learning with patented methods to efficiently call, annotate, and pre-classify variants from raw NGS data. User-friendly features streamline prioritization, simplify interpretation, and expedite reporting.

Published first on TheFly

See Insiders’ Hot Stocks on TipRanks >>

Read More on SOPH:

Trending

Name
Price
Price Change
S&P 500
Dow Jones
Nasdaq 100
Bitcoin

Popular Articles